ZEVRA THERAPEUTICS, INC.

Analyst Reco. Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Real-time Estimate Cboe BZX Other stock markets 07:50:51 14/05/2024 pm IST			5-day change	1st Jan Change
4.885 ^USD	-0.10%		-4.15%	-24.27%

08/05	Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	MT
08/05	Transcript : Zevra Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

William Blair Starts Zevra Therapeutics With Outperform Rating	12/03	MT
HC Wainwright Adjusts Price Target on Zevra Therapeutics to $15 From $10, Keeps Buy Rating	28/12	MT
Canaccord Genuity Adjusts Price Target on Zevra Therapeutics to $20 From $19, Keeps Buy Rating	15/23/15	MT
Maxim Starts Zevra Therapeutics at Buy With $12 Price Target	17/23/17	MT
Cantor Fitzgerald Starts KemPharm at Overweight With $20 Price Target	17/22/17	MT
KemPharm Shares Rise After Canaccord Genuity Initiates Coverage	15/22/15	MT
Canaccord Genuity Starts KemPharm at Buy With $20 Price Target	15/22/15	MT
HC Wainwright Cuts KemPharm's Price Target to $10 From $11, Reiterates Buy Rating	17/22/17	MT
HC Wainwright Upgrades KemPharm to Buy From Neutral, Adjusts Price Target to $11 From $10	31/22/31	MT
KEMPHARM : HC Wainwright Adjusts Price Target on KemPharm to $10 From $12, Maintains Neutral Rating	09/21/09	MT
KEMPHARM : HC Wainwright Downgrades KemPharm to Neutral From Buy, Adjusts Price Target to $12 From $24	04/21/04	MT
KEMPHARM : Roth Capital Starts KemPharm at Buy With $28 Price Target	25/21/25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW